volociximab

02/01/2007 - "Two phase II clinical trials evaluating volociximab in solid tumors are underway. "
02/01/2012 - "Volociximab in cancer."
12/01/2008 - "Patients with advanced solid malignancies were treated with escalating doses of volociximab i.v. administered over 60 minutes. "
02/01/2008 - "Volociximab administered intravenously to rabbits bearing VX2 tumors is detectable on tumor cells and vasculature 45 min post-administration. "
02/01/2008 - "Because volociximab does not cross-react with rodent alpha5beta1, the syngeneic rabbit VX2 carcinoma model was utilized as an alternative to standard mouse xenograft models for the assessment of anti-tumor activity of volociximab. "

11/27/2007 - "Although volociximab has already been tested in open label, pilot phase II clinical trials in melanoma, pancreatic and renal cell cancer, evaluation of the mechanism of action of volociximab has been limited because this antibody does not cross-react with murine alpha5beta1, precluding its use in standard mouse xenograft models. "
02/01/2007 - "PDL Biopharma Inc (formerly Eos Biotechnology Inc) and Biogen Idec Inc are developing volociximab, an angiogenesis-inhibiting chimeric mAb that targets AAB1, a component protein of alpha5/beta1 integrin, for the potential treatment of solid tumors, including renal cell carcinoma. "

12/01/2014 - "The objective of this study was to investigate the M100 and M200 auditory responses in patients with schizophrenia and bipolar disorder and compare them with healthy controls using magnetoencephalography (MEG). "
12/01/2014 - "Overlapping auditory M100 and M200 abnormalities in schizophrenia and bipolar disorder: a MEG study."
12/01/2014 - "However, both the schizophrenia and bipolar disorder patients showed a symmetric M100 and M200 source pattern. "

03/08/2008 - "The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of gemcitabine, bevacizumab, and erlotinib in locally advanced and metastatic adenocarcinoma of the pancreas (abstract #151); iii) final results of the multicenter phase II study on gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (abstract #198); iv) interim results from a phase II study of volociximab in combination with gemcitabine in patients with metastatic pancreatic cancer (abstract #142); v) a pilot study of combination chemotherapy with S-1 and irinotecan for advanced pancreatic cancer (abstract #155); vi) a multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (abstract #212); vii) a phase I/II study of PHY906 plus capecitabine in patients with advanced pancreatic carcinoma (abstract #260); and viii) the final results of a phase II trial of Genexol-PM(R), a novel cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (abstract #269). "

01/01/2021 - "M200 also markedly reduced tumor outgrowth in experimental models of bone metastasis or tumorigenesis, and blunted cancer-associated bone destruction. "
01/01/2021 - "Overall, this study identifies ITGA5 as a mediator of breast-to-bone metastasis and raises the possibility that volociximab/M200 could be repurposed for the treatment of ITGA5-positive breast cancer patients with bone metastases."